SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
22 09 2020
Historique:
received: 18 05 2020
revised: 22 07 2020
accepted: 01 09 2020
pubmed: 18 9 2020
medline: 7 10 2020
entrez: 17 9 2020
Statut: ppublish

Résumé

One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. Here, we show that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays reveal that SARS-CoV-2-related viruses from bats and pangolins also encode truncated ORF3b gene products with strong anti-interferon activity. Furthermore, analyses of approximately 17,000 SARS-CoV-2 sequences identify a natural variant in which a longer ORF3b reading frame was reconstituted. This variant was isolated from two patients with severe disease and further increased the ability of ORF3b to suppress interferon induction. Thus, our findings not only help to explain the poor interferon response in COVID-19 patients but also describe the emergence of natural SARS-CoV-2 quasispecies with an extended ORF3b gene that may potentially affect COVID-19 pathogenesis.

Identifiants

pubmed: 32941788
pii: S2211-1247(20)31174-8
doi: 10.1016/j.celrep.2020.108185
pmc: PMC7473339
pii:
doi:

Substances chimiques

Codon, Nonsense 0
Interferon Type I 0
Viral Regulatory and Accessory Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108185

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Références

Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nature. 2013 Nov 28;503(7477):535-8
pubmed: 24172901
Genes Dev. 1993 Jul;7(7B):1354-63
pubmed: 8330739
PLoS Pathog. 2017 May 5;13(5):e1006348
pubmed: 28475648
Virology. 1998 Dec 20;252(2):324-30
pubmed: 9878611
J Virol. 2007 Jan;81(2):548-57
pubmed: 17108024
Cell Host Microbe. 2020 Jun 10;27(6):870-878
pubmed: 32464097
Proc Int Conf Intell Syst Mol Biol. 1997;5:147-52
pubmed: 9322029
J Gen Virol. 2018 May;99(5):704-709
pubmed: 29611801
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Emerg Infect Dis. 2005 Dec;11(12):1860-5
pubmed: 16485471
J Virol. 2007 Sep;81(18):9812-24
pubmed: 17596301
J Virol. 2014 Jun;88(12):7070-82
pubmed: 24719429
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Respirology. 2003 Nov;8 Suppl:S9-14
pubmed: 15018127
Nature. 2020 Jul;583(7815):286-289
pubmed: 32380510
J Gen Virol. 2012 Feb;93(Pt 2):275-281
pubmed: 22012463
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Infect Dis. 2016 Feb 15;213(4):579-83
pubmed: 26433221
J Thromb Thrombolysis. 2020 Oct;50(3):548-557
pubmed: 32524516
Bioconjug Chem. 2015 Jun 17;26(6):1004-7
pubmed: 26011555
Cell Host Microbe. 2018 Jan 10;23(1):110-120.e7
pubmed: 29324226
Genes Cells. 2017 Feb;22(2):148-159
pubmed: 28084671
Gene. 1991 Dec 15;108(2):193-9
pubmed: 1660837
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Sci Rep. 2014 Jul 02;4:5529
pubmed: 24984862
PLoS Pathog. 2017 Nov 30;13(11):e1006698
pubmed: 29190287
J Virol. 2010 Mar;84(6):2808-19
pubmed: 20071579
J Virol. 2017 Mar 29;91(8):
pubmed: 28148787
J Exp Med. 2020 May 4;217(5):
pubmed: 32232339
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Virol. 2018 Feb 12;92(5):
pubmed: 29237838
Bioinformatics. 2019 Nov 1;35(21):4453-4455
pubmed: 31070718
Nature. 2020 Jul;583(7815):282-285
pubmed: 32218527
Virology. 2003 May 10;309(2):181-9
pubmed: 12758165
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5
pubmed: 16169905
J Virol. 2006 Aug;80(15):7481-90
pubmed: 16840328
J Gen Virol. 2010 Apr;91(Pt 4):1058-62
pubmed: 20016037
Emerg Microbes Infect. 2017 Mar 29;6(3):e14
pubmed: 28352124
Virology. 2017 Jul;507:1-10
pubmed: 28384506
Curr Biol. 2020 Jun 8;30(11):2196-2203.e3
pubmed: 32416074
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Science. 2005 Oct 28;310(5748):676-9
pubmed: 16195424

Auteurs

Yoriyuki Konno (Y)

Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan.

Izumi Kimura (I)

Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan.

Keiya Uriu (K)

Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan; Graduate School of Medicine, the University of Tokyo, Tokyo 1130033, Japan.

Masaya Fukushi (M)

Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 7398511, Japan.

Takashi Irie (T)

Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 7398511, Japan.

Yoshio Koyanagi (Y)

Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 6068507, Japan.

Daniel Sauter (D)

Institute of Molecular Virology, Ulm University Medical Center, Ulm 89081, Germany.

Robert J Gifford (RJ)

MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow G61 1QH, UK.

So Nakagawa (S)

Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa 2591193, Japan.

Kei Sato (K)

Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, the University of Tokyo, Tokyo 1088639, Japan. Electronic address: keisato@g.ecc.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH